News - Shire, Licensing


Current filters:


Popular Filters

Shire sheds Dermagraft assets for $300 million in milestone payments

Shire sheds Dermagraft assets for $300 million in milestone payments


Ireland-headquartered drugmaker Shire (LSE: SHP) has agreed to sell its Dermagraft (human fibroblast-derived…

BiotechnologyDermagraftDiabetesLicensingNorthern EuropeShire

arGEN-X reaches two milestone payments in Shire deal and signs research agreement with Boehringer


Belgium-based biotech firm arGEN-X has reached two important success milestones in its SIMPLE Antibody…

arGEN-XBelgiumBiotechnologyBoehringer IngelheimFinancialGeneticsLicensingRare diseasesResearchShire

Sandoz in deal to market authorized generic of Shire’s Adderall XR in USA

Sandoz in deal to market authorized generic of Shire’s Adderall XR in USA


UK drugmaker Shire says that its subsidiary Shire US Inc has entered into an agreement to supply an authorized…

Adderall XRGenericsLicensingNeurologicalNorth AmericaNovartisSandozShire

Shire and Santaris extend strategic alliance


Danish privately held clinical-stage biopharmaceutical company Santaris Pharma says that its long term…

BiotechnologyLicensingPharmaceuticalRare diseasesResearchSantaris PharmaShire

Acceleron and Shire not to restart ACE-031 program


Privately-held US biotech firm Acceleron Pharma says that Ireland-headquartered Shire (LSE: SHP) has…

Acceleron PharmaACE-031BiotechnologyLicensingPharmaceuticalRare diseasesResearchShire

arGEN-X expands antibody deal with Shire; initiates ARGX-110 trial in cancer


Netherlands and Belgium-based preclinical stage biotech firm arGEN-X, specialized in the discovery and…

arGEN-XARGX-110BiotechnologyLicensingOncologyRare diseasesResearchShire

Ethris enters SNIM modified RNA alliance with Shire


German biotech firm Ethris GmbH has initiated a research based alliance focused on the development and…

BiotechnologyEthris GmbHGeneticsLicensingPharmaceuticalResearchShire

Licensing deals for Amgen/ImmunoGen and Shire/Arrowhead


US biotechnology company ImmunoGen (Nasdaq), which develops anticancer therapeutics using its Targeted…

AmgenArrowhead ResearchBiotechnologyImmunoGenLicensingOncologyPharmaceuticalRare diseasesShire

Shire signs $190 million deal for preclinical CNS drug


Ireland-headquartered drugmaker Shire (LSE: SHP) has exercised its exclusive option to license a novel…

Heptares TherapeuticsLicensingNeurologicalPharmaceuticalShire

Shire partners with Sangamo for hemophilia and other diseases


Ireland-headquartered specialty pharma company Shire plc (LSE: SHP) has entered into a collaboration…

LicensingPharmaceuticalRare diseasesSangamo BioSciencesShire

Shire and Shionogi to jointly develop and commercialize ADHD drugs in Japan


Ireland-headquartered drugmaker Shire (LSE: SHP) has entered into an agreement with Japan’s Shionogi…

Asia-PacificLicensingMarkets & MarketingNeurologicalPharmaceuticalShionogiShire

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top